A photo of Michael Grimley.

Michael S. Grimley, MD

  • Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
  • Professor, UC Department of Pediatrics
I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.
Michael S. Grimley, MD



I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.

As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

My research involves finding treatments for and prevention of viral infections in immunocompromised patients.

When I’m not treating patients or involved in research, I enjoy spending time with my family.

MD: Emory University School of Medicine, Atlanta, GA, 1992.

Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.

Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.

Certification: General Pediatrics, Pediatric Hematology/Oncology.

Licenses: Ohio, Texas.


Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia

Services and Specialties

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Immune Deficiencies and Histiocytosis, Rare Lung Diseases

Research Areas

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Takahashi, T; Al-Kofahi, M; Jaber, M; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Neuberg, DS; Choi, SW; Davis, J; et al. Blood. 2023; 142:700-710.

Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Montiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; et al. Pediatric Blood and Cancer. 2023; 70:e30429.

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Galletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; et al. Transplantation and cellular therapy. 2023; 29:305-310.

Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; et al. The Pediatric Infectious Disease Journal. 2023; 42:119-121.

Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Bender, JD; Oquendo-del Toro, H; Benoit, J; Howell, JC; Badia, P; Davies, SM; Grimley, MS; Jodele, S; Phillips, C; Burns, K; et al. Transplantation and cellular therapy. 2023; 29:130.e1-130.e8.

194 Adherence Barriers in Pediatric Hematopoietic Stem Cell Transplant in an Outpatient Setting. Pai, AL; Deckelman, A; Leone, M; Drake, S; Bills, S; Klink, G; Joffe, N; Grimley, MS; Dandoy, DC E. Transplantation and cellular therapy. 2023; 29:s153-s154.

Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants. Schuster, JE; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Stewart, LS; Stahl, A; Potter, M; Rahman, H; et al. The New England journal of medicine. 2023; 388:374-376.

1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Bahakel, H; Murphy, CR; Frenck, RW; Grimley, M; Phillips, C; Schulert, G; Spearman, P; Courter, JD; Paulsen, GC; Danziger-Isakov, LA. Open Forum Infectious Diseases. 2022; 9.

Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. Bahakel, H; Murphy, C; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Haslam, DB; Phillips, CL; Courter, J; Spearman, P; et al. The Pediatric Infectious Disease Journal. 2022; 41:985-988.

A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab. Benoit, SW; Khandelwal, P; Grimley, MS. Pediatric Transplantation. 2022; 26:e14263.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating